Patent and R&D Disclosure Signals
Using a company's patent filings and R&D spending disclosures as an alternative-data signal for future competitive advantage or product pipeline strength.
Public companies disclose R&D spending in their financial statements, and patent applications become public record months after filing, well before a product ever reaches customers. Some investors track both as an early read on which companies are building durable competitive advantages — a firm quietly filing dozens of patents in a new materials category, or ramping R&D spend well above its peers, may be years ahead of where its current earnings suggest.
The appeal is that patents and R&D commitments are forward-looking and hard to fake cheaply: filing a patent costs real legal and engineering time, so a surge in filings is a costlier signal than a press release. Researchers have also linked patent citation counts — how often other inventors cite a given patent — to the economic value of the underlying innovation, since heavily cited patents tend to represent genuinely useful breakthroughs rather than defensive filings.
The catch is lag and noise. Patents can take one to three years to publish and longer to grant, R&D accounting varies by country and industry, and most patents are never commercialized at all. A biotech filing patents on a drug that later fails trials looks identical, on paper, to one filing patents on a blockbuster — the raw counts alone don't distinguish them.
Patent filings and R&D disclosures give an early, costly-to-fake read on where a company is investing for the future, but raw counts are noisy — citation-weighted patent value and R&D-to-sales trends relative to peers are more informative than filing counts alone.
Related concepts
Further reading
- Kogan, Papanikolaou, Seru, Stoffman, 'Technological Innovation, Resource Allocation, and Growth'